Literature DB >> 23974690

Comorbidities in psoriasis.

Sanjeev J Aurangabadkar1.   

Abstract

Moderate to severe psoriasis is associated with concomitant diseases that may have a significant impact on patients. It is necessary for the treating physician to recognize these concomitant diseases, known as comorbidities, early as they influence the management options. Important comorbidities are psoriatic arthritis, metabolic syndrome, Crohn's disease, depression, and cancer. Patients with severe psoriasis may be at an increased risk for myocardial infarction and this subgroup of patients tends to have a reduced life expectancy. The presence of co-morbid diseases is associated with an increase in concomitant medication, some of which may worsen psoriasis; conversely, systemic treatment of psoriasis with certain drugs may impact the co-morbid conditions. As dermatologists are the primary health-care providers for psoriasis, adequate knowledge of comorbidities helps in choosing the appropriate therapy as well as timely intervention.

Entities:  

Mesh:

Year:  2013        PMID: 23974690     DOI: 10.4103/0378-6323.115506

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  7 in total

1.  Carotid intima-media thickness and epicardial fat thickness predict precoronary artery disease status in psoriasis.

Authors:  Banavasi Shanmukha Girisha; Shajahan Shibina; U Raghuraja; K Subramanyam
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

2.  Kidney involvement in psoriasis: a case-control study from China.

Authors:  Fang Ren; Min Zhang; Liying Hao; Hong Sang
Journal:  Int Urol Nephrol       Date:  2017-09-22       Impact factor: 2.370

3.  Comorbidities of Psoriasis - Exploring the Links by Network Approach.

Authors:  Sudharsana Sundarrajan; Mohanapriya Arumugam
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

4.  Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions.

Authors:  Vinay Singh
Journal:  Dermatol Res Pract       Date:  2016-11-02

5.  Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis.

Authors:  Joanna Salomon; Łukasz Matusiak; Danuta Nowicka-Suszko; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2017-08-28       Impact factor: 4.711

6.  Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database.

Authors:  Timothy Fitzgerald; Aimee M Near; Hyunchung Kim; Amanda Teeple; Mobolaji Olurinde; Katelyn Rowland
Journal:  Dermatol Ther (Heidelb)       Date:  2022-02-24

Review 7.  Oxidative Stress Induced by High Salt Diet-Possible Implications for Development and Clinical Manifestation of Cutaneous Inflammation and Endothelial Dysfunction in Psoriasis vulgaris.

Authors:  Ivana Krajina; Ana Stupin; Marija Šola; Martina Mihalj
Journal:  Antioxidants (Basel)       Date:  2022-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.